Biocysan Patent Granted in the USA by USPTO

PRLog (Press Release) - Oct. 2, 2012 - October 1st 2012 - Bio3 Research S.r.l., Milan – Italy, has been granted by the United States Patent and Trademark Office (USPTO) the US patent No. 101/583,334 which claims the oral use of L-cysteine (Biocysan®), in patients with impaired renal functions who are exposed to severe anemia and to oxidative stress.

The US patent grant strengthens Bio3 Research patent portfolio with Biocysan®.
In addition to the USA, Biocysan® patents have now been granted to Bio3 Research in Canada, Mexico (NAFTA) and also in Europe. Biocysan® patent is pending (very final phase) in Japan.

Bio3 Research has started the commercialisation in several countries, via local distributors, of Biocysan® (oral L-cysteine – pulse release formulation), a dietary supplement, based on the captioned granted patents, to counteract oxidative stress in chronic kidney disease patients and to alleviate anemia.
Bio3 Research has also started Biocysan® worldwide sale via e-commerce.

Biocysan® acts as support treatment in Chronic Kidney Disease patients to prevent severe anemia, due to Glutathione (GSH) low levels and to reduce oxidative stress, via re-establishing Glutathione levels (GSH). GSH is instrumental for the synthesis of stable erythrocytes which ultimately are the key transporters of oxigen in the body cells. No other oral Pulse Release formulations based on L-Cysteine are available in the market.